Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.

Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has multiple effective treatment options available and new therapeutic strategies are being actively explored to further increase the treatment options for patients with IBD. Furthermore, biologic agents and small molecule drugs developed for ulcerative colitis (UC) and Crohn's disease (CD) have evolved toward fewer side effects and more accurate targeting. Novel inhibitors that target cytokines (such as IL-12/23 inhibitors, PDE4 inhibitors), integrins (such as integrin inhibitors), cytokine signaling pathways (such as JAK inhibitors, SMAD7 blocker) and cell signaling receptors (such as S1P receptor modulator) have become the preferred treatment choice for many IBD patients. Conventional therapies such as 5-aminosalicylic acid, corticosteroids, immunomodulators and anti-tumor necrosis factor agents continue to demonstrate therapeutic efficacy, particularly in combination with drug therapy. This review integrates research from chemical, biological and adjuvant therapies to evaluate current and future IBD therapies, highlighting the mechanism of action of each therapy and emphasizing the potential of development prospects.

• Publication year

  2023

• Venue

  Cytokine & growth factor reviews

• Publication date

  2023-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cytogfr.2023.07.001PMID 37455149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

  2023cited by this paper
• Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease.

  2022cited by this paper
• Upadacitinib for ulcerative colitis.

  2022cited by this paper
• Deucravacitinib: First Approval

  2022cited by this paper
• Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases

  2021cited by this paper
• Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.

  2021cited by this paper
• Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.

  2021cited by this paper
• Outcomes in Antiplatelet‐Associated Intracerebral Hemorrhage in the TICH‐2 Randomized Controlled Trial

  2021cited by this paper
• Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis

  2021cited by this paper
• Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update.

  2021cited by this paper
• Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.

  2021cited by this paper
• 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future

  2021cited by this paper
• The microbiome and inflammatory bowel disease.

  2020cited by this paper
• The four epidemiological stages in the global evolution of inflammatory bowel disease

  2020cited by this paper
• JAK Inhibitors: Back to Small Molecules for the Treatment of IBD

  2020cited by this paper
• Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease.

  2020cited by this paper
• PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD

  2020cited by this paper
• Filgotinib: First Approval

  2020cited by this paper
• Synergic interactions between polyphenols and gut microbiota in mitigating inflammatory bowel diseases.

  2020cited by this paper
• Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases

  2020cited by this paper
• The historical role and contemporary use of corticosteroids in inflammatory bowel disease.

  2020cited by this paper
• JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

  2020cited by this paper
• Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.

  2020cited by this paper
• Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.

  2020cited by this paper
• Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.

  2019cited by this paper
• Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

  2019cited by this paper
• Mechanisms of Disease: Inflammatory Bowel Diseases.

  2019cited by this paper
• Efficacy of JAK inhibitors in Crohn’s Disease

  2019cited by this paper
• Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target.

  2019cited by this paper
• Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation.

  2019cited by this paper
• Anti-MADCAM therapy for ulcerative colitis

  2019cited by this paper
• Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis.

  2019cited by this paper
• Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

  2019cited by this paper
• Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis.

  2019cited by this paper
• Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances

  2019cited by this paper
• Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study

  2019cited by this paper
• A Review of Dietary Therapy for IBD and a Vision for the Future

  2019cited by this paper
• Off-label studies on apremilast in dermatology: a review

  2019cited by this paper
• Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.

  2018cited by this paper
• IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting

  2018cited by this paper
• 349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease

  2018cited by this paper
• Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors

  2018cited by this paper
• Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease

  2018cited by this paper
• Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.

  2018cited by this paper
• Transforming Growth Factor-β1/Smad7 in Intestinal Immunity, Inflammation, and Cancer

  2018cited by this paper
• Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.

  2018cited by this paper
• Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

  2017cited by this paper
• Apremilast: A Review in Psoriasis and Psoriatic Arthritis

  2017cited by this paper
• Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

  2017cited by this paper
• Modulation of sphingosine-1-phosphate in inflammatory bowel disease.

  2017cited by this paper
• JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

  2017cited by this paper
• PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue

  2017cited by this paper
• Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

  2017cited by this paper
• Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects

  2017cited by this paper
• Current and emerging therapeutic targets for IBD

  2017cited by this paper
• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  2017cited by this paper
• Ustekinumab: A Review in Moderate to Severe Crohn’s Disease

  2017cited by this paper
• Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

  2016cited by this paper
• Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis

  2016cited by this paper
• Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster

  2016cited by this paper
• The safety of vedolizumab for ulcerative colitis and Crohn's disease

  2016cited by this paper
• Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

  2016cited by this paper
• Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

  2016cited by this paper
• Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort

  2016cited by this paper
• An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.

  2016cited by this paper
• AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial.

  2016cited by this paper
• Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn’s disease

  2016cited by this paper
• The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

  2016cited by this paper
• 855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial

  2016cited by this paper
• 812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis

  2016cited by this paper
• Aminosalicylates for induction of remission or response in Crohn's disease.

  2016cited by this paper
• Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

  2016cited by this paper
• Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future

  2016cited by this paper
• Biologic agents for IBD: practical insights

  2015cited by this paper
• The TGF-&bgr;/Smad System in IBD Pathogenesis

  2015cited by this paper
• Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

  2015cited by this paper
• The clinical implications of thalidomide in inflammatory bowel diseases

  2015cited by this paper
• 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets.

  2015cited by this paper
• Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.

  2014cited by this paper
• Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.

  2014cited by this paper
• A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.

  2014cited by this paper
• A phase II study of laquinimod in Crohn's disease

  2014cited by this paper
• Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

  2014cited by this paper
• IBD in 2013: Enriching the therapeutic armamentarium for IBD

  2014cited by this paper
• Janus kinase inhibitors in autoimmune diseases

  2013cited by this paper
• AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease

  2013cited by this paper
• A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

  2013cited by this paper
• Impact of polyphenols and polyphenol-rich dietary sources on gut microbiota composition.

  2013cited by this paper
• Su1211 Comparative Long-Term Outcomes of Tacrolimus, Cyclosporine and Infliximab for Steroid-Refractory Ulcerative Colitis - Week 52 Results Swiss IBD Cohort Study

  2013cited by this paper
• Placebo-controlled trial of oral laquinimod for multiple sclerosis.

  2012cited by this paper
• Tetomilast: new promise for phosphodiesterase-4 inhibitors?

  2012cited by this paper
• Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience

  2012cited by this paper
• Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis

  2012cited by this paper
• A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

  2012cited by this paper
• Fingolimod for multiple sclerosis.

  2012cited by this paper
• Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment

  2011cited by this paper
• Safety, Immunogenicity and Clinical Phase I-II Results of TNFα-Kinoid Immunotherapeutic in Crohn's Disease Patients

  2011cited by this paper
• The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

  2011cited by this paper
• Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

  2011cited by this paper
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  2011cited by this paper

• Construction of Engineered EcN Bacteria Constitutively Highly Expressing RtSOD/RtSOD-CAT Fusion Protein and its Protective Effect on UC Mice

  2026cites this paper
• Cobalt Metal-organic Framework Alleviates DSS-Induced Ulcerative Colitis Via Barrier-protective and Immunomodulatory Effects.

  2026cites this paper
• Monogenic forms of inflammatory bowel disease: Genetic mechanisms, models, and clinical implications

  2026cites this paper
• Maillard conjugation potentiates the barrier-restoring activity of collagen peptides and galactooligosaccharides by remodeling the gut metabolic profile

  2026cites this paper
• Mesenchymal stromal cell-free therapies for the treatment of inflammatory bowel disease.

  2026cites this paper
• Oral delivery of infliximab via self-assembled nano-in-microspheres for enhanced inflammatory bowel disease therapy.

  2026cites this paper
• Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea

  2026cites this paper
• Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules

  2026cites this paper
• Pharmacogenomic Pathways Underlying Variable Vedolizumab Response in Crohn’s Disease Patients: A Rare-Variant Analysis

  2026cites this paper
• Targeting the plasticity of intestinal neutrophils: bidirectional regulation strategies by natural products

  2026cites this paper
• Linderane from Lindera aggregata Attenuates Ulcerative Colitis by Suppressing IL-6/STAT3-Mediated Th17 Differentiation and Apoptosis Resistance.

  2025cites this paper
• Assessing the therapeutic potential of rutin in alleviating symptoms of inflammatory bowel disease: a meta-analysis

  2025cites this paper
• Clinacanthus nutans restores the intestinal barrier in UC via regulatings oxidative stress to suppress the occurrence of ferroptosis

  2025cites this paper
• Fecal metaproteomics enables functional characterization of remission in patients with inflammatory bowel disease.

  2025cites this paper
• Converting indoprofen to moderate selective COX-2 inhibitors: Design, synthesis and biological evaluation.

  2025cites this paper
• Integration of Multi-Omics and Network Pharmacology Analysis Reveals the Mechanism of Qingchang Huashi Jianpi Bushen Formula in Repairing the Epithelial Barrier of Ulcerative Colitis

  2025cites this paper
• Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review

  2025cites this paper
• Comparative Efficacy of Different Targeted Therapies in Patients With Moderate‐to‐Severe Ulcerative Colitis: Systematic Review/Network Meta‐Analysis and Mechanistic Overview

  2025cites this paper
• The preventive effect of solubilized sturgeon oil on dextran sulfate sodium-induced ulcerative colitis via inflammation attenuation and intestinal microbiota regulation.

  2025cites this paper
• Pannexin‐1 Aggravates Inflammatory Bowel Disease via Unbalancing Macrophage Polarisation and Triggering Ferroptosis in Mice

  2025cites this paper
• Lovastatin alleviates DSS-induced colitis by modulating macrophage polarization via the PPARγ-NF-κB pathway.

  2025cites this paper
• Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers

  2025cites this paper
• Pathogenesis guided application of nanozymes in the treatment of inflammatory bowel disease

  2025cites this paper
• Mesenchymal stem cell in immunomodulation of dendritic cells: Implications for inflammatory bowel disease therapy.

  2025cites this paper
• Effectiveness and safety of non-pharmacological therapies for the treatment of inflammatory bowel disease: a network meta-analysis

  2025cites this paper
• Transglutaminase 2 modulates inflammatory angiogenesis via vascular endothelial growth factor receptor 2 pathway in inflammatory bowel disease.

  2025cites this paper
• AQP9 and IFITM1 as drivers of immune infiltration and tumor progression in IBD-associated colorectal cancer: from computational insights to experimental validation

  2025cites this paper
• Exploring the Regulatory Mechanism of Total Alkaloids from Portulaca oleracea L. in UC Treatment Based on Network Pharmacology

  2025cites this paper
• Ucerative Colitis and Crohn’s Disease in Childhood: Topical Issues and Solutions

  2025cites this paper
• Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database

  2025cites this paper
• The Research Progress of Immune Checkpoints CTLA-4, PD-1/PD-L1 and VISTA in Ulcerative Colitis

  2025cites this paper
• Immunocytes Mediate the Effects of Gut Microbiome on Inflammatory Bowel Disease: Insights From a Mendelian Randomization Study

  2025cites this paper
• Discovery of 7-azaindole-3-acrylamide inhibitors of inflammasomes/IL-1β for the treatment of inflammatory bowel disease.

  2025cites this paper
• Akkermansia muciniphila: A key player in gut microbiota-based disease modulation.

  2025cites this paper
• Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis

  2025cites this paper
• A New Paradigm for Precision Drug Delivery in Inflammatory Bowel Disease: Effective Transfer, Enhanced Retention, and Pathology‐Targeting Treatment via Biomaterials and Engineered Platforms

  2025cites this paper
• Downregulation of IFIT3 Relieves the Inflammatory Response in Ulcerative Colitis via Selectively Regulating Macrophage M1 Polarization and the STAT1/2 Signaling Pathway

  2025cites this paper
• Exploring the molecular mechanism of Crohn's disease and rheumatoid arthritis: a bioinformatics and functional analysis approach.

  2025cites this paper
• Oral multifunctional gel beads for the targeted treatment of inflammatory bowel disease.

  2025cites this paper
• Ultrafast in situ formed robust and adhesive photo-crosslinked hydrogel encapsulating curcumin for ulcerative colitis alleviation via regulating inflammation and gut microbiota

  2025cites this paper
• A ROS-responsive nanocarrier co-delivering cerium nanozymes and thalidomide for synergistic ulcerative colitis therapy

  2025cites this paper
• A Review on Functional Foods Regulate the Gut Microbiota and Mast Cell Function in Inflammatory Bowel Disease (IBD).

  2025cites this paper
• Probiotics and Postbiotics Produced by Lacticaseibacillus rhamnosus 1.0320 Isolated from Traditional Fermented Dairy Products Alleviate DSS-Induced Colitis by Modulating the Gut Microbiota and Intestinal Metabolism.

  2025cites this paper
• Fecal Calprotectin and CRP: Noninvasive Biomarkers in IBD

  2025cites this paper
• Memory in Misfire: The Gut Microbiome-Trained Immunity Circuit in Inflammatory Bowel Diseases

  2025cites this paper
• Therapeutic preferences of upadacitinib for patients with inflammatory bowel diseases: a nationwide study among Chinese physicians

  2025cites this paper
• Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.

  2025cites this paper
• Synergistic hemostasis and inflammation resolution for reversing IBD: A macrophage-based enzyme-responsive liposomal strategy

  2025cites this paper
• Genetically engineered elastin-like polypeptide nanoparticles for enhanced protein delivery and therapeutic modulation in inflammatory bowel disease.

  2025cites this paper
• Combining Network Pharmacology, Molecular Docking, and Integrative Studies to Explore the Mechanism of Helminthostachys zeylanica in Alleviating Ulcerative Colitis

  2025cites this paper
• Surface modification of probiotics at single-cell resolution: Strategies, applications, and future directions in inflammatory bowel disease

  2025cites this paper
• Microbiota-targeted strategies in IBD: therapeutic promise of 2′-fucosyllactose and beyond

  2025cites this paper
• Identification of hypoxia-associated genes as potential diagnostic biomarkers for ulcerative colitis.

  2025cites this paper
• Integrated multi-omics, network pharmacology, and experimental validation reveal that Yinmeikuijie decoction alleviates ulcerative colitis by inhibiting arachidonic acid metabolism.

  2025cites this paper
• Thioketal-linked glycol chitosan nanosystem for targeted and sustained drug delivery of mesalazine in inflammatory bowel disease.

  2025cites this paper
• Patients with inflammatory bowel disease exhibit increased susceptibility to HCoV-NL63

  2025cites this paper
• [Niranthin ameliorates Crohn's disease-like enteritis in mice by inhibiting intestinal epithelial cell apoptosis and protecting intestinal barrier via modulating p38/JNK signaling].

  2025cites this paper
• Astaxanthin alleviates DSS-induced ulcerative colitis in mice associated with Nrf2-mediated ferroptosis independently of gut microbiota modulation.

  2025cites this paper
• Screening of Sinapic acid as a polyphenol stabilizing agent for enhanced miR-124 delivery in ulcerative colitis therapy.

  2025cites this paper
• Recombinant MAM from Faecalibacterium duncaniae exhibits a protective effect in DNBS-induced colitis

  2025cites this paper
• Integrin Inhibitors for Ulcerative Colitis Treatment.

  2025cites this paper
• Emu Oil: A Potential Adjunct to Inflammatory Bowel Disease Treatment?

  2025influential citation
• Lacto-N-Triose II Alleviates DSS-Induced Colitis via Gut Microbiota and Metabolites Associated with the PI3K-Akt Pathway.

  2025cites this paper
• Injectable DAT-ALG Hydrogel Mitigates Senescence of Loaded DPMSCs and Boosts Healing of Perianal Fistulas in Crohn's Disease.

  2025cites this paper
• Screen of propionate-producing probiotic strains in attenuating murine colitis by modulating immune response and restoring the intestinal barrier

  2025cites this paper
• Correlation and diagnostic significance of CD4 T cell subsets and NLRP3 inflammasome in ulcerative colitis: the role of the NLRP3/T-bet/GATA3 axis

  2025cites this paper
• Chemical Composition of Cynanchum auriculatum Royle Ex Wight and Its Potential Role in Ameliorating Colitis

  2025cites this paper
• Cynaroside ameliorates TNBS-induced colitis by inhibiting intestinal epithelial cell apoptosis via the PI3K/AKT signalling pathway

  2025cites this paper
• SAA3 deficiency exacerbates intestinal fibrosis in DSS-induced IBD mouse model

  2025cites this paper
• Interprofessional approach to personalized medication management and therapy optimization in IBD care

  2025cites this paper
• Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review

  2025cites this paper
• Oral colon-targeted delivery of recombinant human MANF for alleviation of ulcerative colitis

  2025cites this paper
• Proteomic analysis reveals that Acalypha australis L. mitigates chronic colitis by modulating the FABP4/PPARγ/NF-κB signaling pathway.

  2025cites this paper
• Dietary succinate supplementation alleviates DSS-induced colitis via the IL-4Rα/Hif-1α Axis.

  2025cites this paper
• Biosilicification-mimicking chiral nanostructures for targeted treatment of inflammatory bowel disease

  2025cites this paper
• Oral Targeted MXenzyme – Armed Probiotic Regulates Intestinal Redox and Microbiota Homeostasis to Synergistically Ameliorate Ulcerative Colitis

  2025cites this paper
• Biomarkers and Underlying Pathways for Prediction of Response to Vedolizumab Therapy in Inflammatory Bowel Disease

  2025influential citation
• Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis

  2025cites this paper
• In Situ Self-Assembled Probe for Antioxidant and Anti-Inflammatory Therapy of Inflammatory Bowel Disease.

  2025cites this paper
• Yerba Mate (Ilex paraguariensis) Reduces Colitis Severity by Promoting Anti-Inflammatory Macrophage Polarization

  2024cites this paper
• Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review

  2024cites this paper
• Mendelian randomization reveals predictive, preventive, and personalized insights into inflammatory bowel disease: the role of gut microbiome and circulating inflammatory proteins

  2024cites this paper
• The potential of targeting TREM-1 in IBD.

  2024cites this paper
• The CCL5/CCR5 axis in ulcerative colitis.

  2024cites this paper
• The role of suppressor of cytokine signaling 3 in inflammatory bowel disease and its associated colorectal cancer.

  2024cites this paper
• Molecular Docking of Key Compounds from Acacia Honey and Nigella sativa Oil and Experimental Validation for Colitis Treatment in Albino Mice

  2024cites this paper
• Protective effect of Huanglian Pingwei San on DSS-induced ulcerative colitis in mice through amelioration of the inflammatory response and oxidative stress

  2024cites this paper
• Cucurbitacin IIa Ameliorates DSS-Induced Ulcerative Colitis via Enhancing Intestinal Barrier Function and Inhibiting PERK/ATF4/CHOP Signaling Pathway

  2024cites this paper
• Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease

  2024cites this paper
• Fucoxanthin Alleviates Dextran Sulfate Sodium-Induced Colitis and Gut Microbiota Dysbiosis in Mice.

  2024cites this paper
• Colon delivery of resveratrol for the treatment of inflammatory bowel disease

  2024cites this paper
• Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis

  2024cites this paper
• Krill Oil and Its Bioactive Components as a Potential Therapy for Inflammatory Bowel Disease: Insights from In Vivo and In Vitro Studies

  2024cites this paper
• Gut-tropic T cells and extra-intestinal autoimmune diseases.

  2024cites this paper
• Bazedoxifene attenuates dextran sodium sulfate-induced colitis in mice through gut microbiota modulation and inhibition of STAT3 and NF-κB pathways.

  2024cites this paper
• Global Epidemiology and Geographic Variations of Pediatric-Onset Inflammatory Bowel Disease: A Comprehensive Analysis of the Global Burden of Disease Study 1990 to 2019.

  2024cites this paper
• The Role of TRP Channels in Sepsis and Colitis

  2024cites this paper
• Polyphenolic Nanoparticle-Modified Probiotics for Microenvironment Remodeling and Targeted Therapy of Inflammatory Bowel Disease.

  2024cites this paper
• Biomarkers in inflammatory bowel disease: a practical guide

  2024cites this paper
• Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis

  2024cites this paper